Alpha Synuclein Market Size, Share, Analysis, Industry Report and Forecast 2022-2028

The global alpha-synuclein market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Alpha-synuclein is a neuronal protein that is encoded by the SNCA gene in humans and is abundant in the brain, while smaller amounts of it are found in the heart, muscle, and other tissues. Alpha-synuclein is a protein that regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Abnormal alpha-synuclein depositions (?-synucleinopathies) in neurons, nerve fibers, or glia cells are the causes for several neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Parkinson's disease is the most common progressive neurodegenerative movement disorder with significant prevalence and incidences across the globe.

To Request a Sample of our Report on Alpha Synuclein Market: https://www.omrglobal.com/request-sample/alpha-synuclein-market

Increasing prevalence and incidences of Parkinson's disease globally is one of the major factors that is augmenting the growth of the global alpha-synuclein market. A significant increase in the number of Parkinson's disease patients along with the limited treatment solutions for this disease serves as a potential growth factor for the market globally. Furthermore, industry players are aggressively focusing on the development of treatment solutions for Parkinson's disease through alpha-synuclein which is further boosting the market growth. For instance, Roche presented its monoclonal antibody (mAb)-targeting alpha (?)-synuclein, prasinezumab, for the treatment of Parkinson's disease at the 15th International Virtual Conference on Alzheimer's disease and Parkinson's disease (AD/PD) 2021. Prasinezumab is an ?-synuclein mAb administered intravenously as an infusion.

Some key players operating in the market include F. Hoffmann La-Roche AG, and H. Lundbeck A/S, among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches, development in the existing product portfolio, and so on.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Type

· By Application

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: F. Hoffmann La-Roche AG, and H. Lundbeck A/S, among others.

(Get 15% Discount on Buying this Report)

A full Report of Global Incubator Devices Market is Available @ https://www.omrglobal.com/industry-reports/alpha-synuclein-market

Global Alpha Synuclein Market Report by Segment

By Type

· AV-1950R

· AV-1947D

· BAN-0805

· BIIB-054

· DPC-003

· Others

By Application

· Multiple System Atrophy

· Neurodegenerative Disease

· Lewy Body Dementia

· Others

Global Alpha Synuclein Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.